Presentation is loading. Please wait.

Presentation is loading. Please wait.

The key pathological mechanisms underlying vascular changes in pulmonary hypertension (PH). The key pathological mechanisms underlying vascular changes.

Published byMarian Horton Modified over 5 years ago

Similar presentations

Presentation on theme: "The key pathological mechanisms underlying vascular changes in pulmonary hypertension (PH). The key pathological mechanisms underlying vascular changes."— Presentation transcript:

1 The key pathological mechanisms underlying vascular changes in pulmonary hypertension (PH).
The key pathological mechanisms underlying vascular changes in pulmonary hypertension (PH). Potential new therapies for PH are also indicated. AEC: alveolar epithelial cell; vWF: von Willebrand factor; TXA2: thromboxane A2; NO: nitric oxide; EPC: endothelial progenitor cell; ET-1: endothelin-1; PGI2: prostaglandin I2; sGC: soluble guanylate cyclase; cGMP: cyclic guanosine monophosphate; 5-HT: 5-hydroxytryptamine; VEGF: vascular endothelial growth factor; bFGF: basic fibroblast growth factor; TGF-α: transforming growth factor-α; PDGF: platelet-derived growth factor; HGF: hepatocyte growth factor; PPARγ: peroxisome proliferator-activated receptor-γ; STAT3: signal transducer and activator of transcription 3; NFAT: nuclear factor of activated T-cells; MCP-1: monocyte chemoattractant protein-1; TNF: tumour necrosis factor; IL: interleukin; FKN: fractalkine; CCL: chemokine ligand; cAMP: cyclic adenosine monophosphate. Reproduced from [6] with permission from the publisher. M.R. Wilkins Eur Respir Rev 2012;21:19-26 ©2012 by European Respiratory Society

Download ppt "The key pathological mechanisms underlying vascular changes in pulmonary hypertension (PH). The key pathological mechanisms underlying vascular changes."

Similar presentations

BDNF: brain-derived neurotrophic factor CRP: C-reactive protein

BDNF: brain-derived neurotrophic factor CRP: C-reactive protein
Perioperative Statin Therapy for Patients Undergoing Coronary Artery Bypass Grafting  Amr F. Barakat, MD, Marwan Saad, MD, PhD, Ahmed Abuzaid, MD, Amgad.

Perioperative Statin Therapy for Patients Undergoing Coronary Artery Bypass Grafting  Amr F. Barakat, MD, Marwan Saad, MD, PhD, Ahmed Abuzaid, MD, Amgad.
Copyright © 2003 American Medical Association. All rights reserved.

Copyright © 2003 American Medical Association. All rights reserved.
Immune mediators of tissue remodelling and lung function impairment in tuberculosis. Immune mediators of tissue remodelling and lung function impairment.

Immune mediators of tissue remodelling and lung function impairment in tuberculosis. Immune mediators of tissue remodelling and lung function impairment.
Endothelium-derived mediators: the vasodilators prostacyclin (PGI2) and nitric oxide (NO) and the vasoconstrictor endothelin (ET-1). Endothelium-derived.

Endothelium-derived mediators: the vasodilators prostacyclin (PGI2) and nitric oxide (NO) and the vasoconstrictor endothelin (ET-1). Endothelium-derived.
Figure 3 Extracellular stimuli to HSC activation

Figure 3 Extracellular stimuli to HSC activation
Perioperative Statin Therapy for Patients Undergoing Coronary Artery Bypass Grafting  Amr F. Barakat, MD, Marwan Saad, MD, PhD, Ahmed Abuzaid, MD, Amgad.

Perioperative Statin Therapy for Patients Undergoing Coronary Artery Bypass Grafting  Amr F. Barakat, MD, Marwan Saad, MD, PhD, Ahmed Abuzaid, MD, Amgad.
Liver regeneration Journal of Hepatology

Liver regeneration Journal of Hepatology
Chlamydophila pneumoniae

Chlamydophila pneumoniae
S. S. Pullamsetti, R. Savai, W. Janssen, B. K. Dahal, W. Seeger, F

S. S. Pullamsetti, R. Savai, W. Janssen, B. K. Dahal, W. Seeger, F
The key pathways and classes of drugs that have been approved for the treatment of pulmonary arterial hypertension. The key pathways and classes of drugs.

The key pathways and classes of drugs that have been approved for the treatment of pulmonary arterial hypertension. The key pathways and classes of drugs.
Physiological changes in pulmonary arterial hypertension (PAH) patients which occur in response to pregnancy. Physiological changes in pulmonary arterial.

Physiological changes in pulmonary arterial hypertension (PAH) patients which occur in response to pregnancy. Physiological changes in pulmonary arterial.
Figure 2 Signalling molecules and pathways involved in HSC activation

Figure 2 Signalling molecules and pathways involved in HSC activation
Figure 1 Currently recognized factors that influence the development of scleroderma renal crisis Figure 1 | Currently recognized factors that influence.

Figure 1 Currently recognized factors that influence the development of scleroderma renal crisis Figure 1 | Currently recognized factors that influence.
Figure 1 The central role of chronic prostate

Figure 1 The central role of chronic prostate
Vascular endothelial dysfunction in cirrhosis

Vascular endothelial dysfunction in cirrhosis
Daniel A. Langer, Vijay H. Shah  Journal of Hepatology 

Daniel A. Langer, Vijay H. Shah  Journal of Hepatology 
The pro-inflammatory and chemotactic cytokine microenvironment of the abdominal aortic aneurysm wall: A protein array study  Rachel K. Middleton, BSc,

The pro-inflammatory and chemotactic cytokine microenvironment of the abdominal aortic aneurysm wall: A protein array study  Rachel K. Middleton, BSc,
Craig H Selzman, MD, Stephanie A Miller, MD, Alden H Harken, MD 

Craig H Selzman, MD, Stephanie A Miller, MD, Alden H Harken, MD 
Mechanisms of rIPC. Mechanisms of rIPC. AP-1, activator protein-1; cGMP, cyclic guanosine monophosphate; CGRP, calcitonin gene-related peptide; COX2, cyclooxygenase.

Mechanisms of rIPC. Mechanisms of rIPC. AP-1, activator protein-1; cGMP, cyclic guanosine monophosphate; CGRP, calcitonin gene-related peptide; COX2, cyclooxygenase.

Similar presentations

Ads by Google